Instylla Launches Embrace Hydrogel Embolic System
Instylla, Inc., a pioneering company in the field of embolization technologies, has proudly reported a significant milestone with the commercial launch of the Embrace Hydrogel Embolic System. This innovative device stands out as the first and only liquid embolic product specifically approved for the embolization of hypervascular tumors. This approval was based on a thorough prospective, randomized, controlled clinical trial that laid the groundwork for its use in clinical settings.
Significance of the First Commercial Procedure
The initial commercial procedure was successfully carried out by Dr. Ripal Gandhi, an Interventional Oncologist specialized in treating complex cases. Dr. Gandhi described the event as a pivotal moment in the advancement of interventional radiology. He noted the importance of ongoing innovation and how tools like the Embrace Hydrogel Embolic System enhance ability to treat complex diseases with greater precision. At the heart of this system is its capability for deep, distal penetration into the tumor vascular bed, allowing treatment to be tailored to fit individual patient needs.
Overview of Hypervascular Tumors
Hypervascular tumors frequently pose great challenges in clinical settings due to their high blood supply, which complicates conventional surgical approaches. These tumors are often found in vital organs including the liver, kidneys, and bones, and represent a large segment of cancers treated by interventional radiologists. With over 150,000 embolization procedures performed annually in the United States, the necessity for effective treatment options like the Embrace system is abundantly clear.
How Embrace Works
The Embrace Hydrogel Embolic System works through the innovative combination of two low-viscosity liquid precursors that, when injected, form a soft polyethylene glycol hydrogel within the vascular compartment. This mechanism allows it to create rapid and prolonged occlusion at the targeted site, promoting enhanced patient outcomes. The unique design aims to liquefy via hydrolysis over a period of about eleven months, thereby providing an extended therapeutic effect.
Comments from Leadership
Sean Boyle, the Chief Executive Officer of Instylla, expressed his pride in witnessing the transition of the Embrace Hydrogel System into clinical practice following its FDA approval. He emphasized the transformative nature of this platform technology designed to meet critical needs for cancer patients suffering from hypervascular tumors. The company aims to support medical professionals in delivering enhanced care through innovative solutions.
About Instylla, Inc.
Founded in 2017 and based in Bedford, Massachusetts, Instylla is on a mission to push the boundaries of interventional radiology through the development of resorbable embolic agents. Targeting initial applications within interventional oncology and peripheral hemostasis, Instylla is backed by leading venture capital groups and aims to revolutionize treatment options for patients.
Frequently Asked Questions
What is the Embrace Hydrogel Embolic System?
The Embrace Hydrogel Embolic System is a liquid embolic product approved for treating hypervascular tumors, enabling targeted and effective embolization.
Who performed the first commercial procedure?
The first commercial procedure was performed by Dr. Ripal Gandhi, an Interventional Oncologist recognized for his expertise in complex tumor cases.
Why are hypervascular tumors significant?
Hypervascular tumors are significant due to their high blood supply, which complicates surgery and makes embolization a common treatment strategy.
What is the mechanism of action of Embrace HES?
The Embrace HES works by mixing two liquid precursors that form a hydrogel, allowing targeted occlusion of the tumor's blood supply.
What is Instylla's mission?
Instylla aims to advance interventional radiology through innovative resorbable embolic agents for improved patient outcomes in oncology and hemostasis.
